Related Experiment Video

Updated: May 25, 2026

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

Tobramycin for the treatment of bacterial pneumonia in children

Meenakshi Bothra1, Rakesh Lodha, Sushil Kumar Kabra

  • 1All India Institute of Medical Sciences, Department of Pediatrics, New Delhi 110029, India.

Expert Opinion on Pharmacotherapy
|February 2, 2012
PubMed

Insights

Inhaled tobramycin offers an effective, convenient treatment for cystic fibrosis (CF) patients with Pseudomonas infections, reducing hospitalizations and systemic antibiotic use. This advanced delivery method shows promise for other respiratory conditions as well.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Pulmonology

Background:

  • Community-acquired lower respiratory tract infections (LRTI) are often treatable with standard antibiotics.
  • However, Gram-negative bacilli cause difficult-to-manage LRTI in immunocompromised patients, those with cystic fibrosis (CF), or on ventilators.
  • Tobramycin is an effective treatment for these complex cases.

Purpose of the Study:

  • To review the antimicrobial activity, pharmacology, clinical efficacy, and safety of tobramycin.
  • To highlight advances in tobramycin delivery and its application in various respiratory conditions.

Main Methods:

  • Comprehensive review of existing literature on tobramycin.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Evaluation of clinical efficacy and safety profiles.

Main Results:

  • Inhalational tobramycin is a significant advancement for pediatric CF patients with Pseudomonas infections.
  • This route allows for easier home administration, higher doses, and improved outcomes.
  • Evidence suggests reduced hospitalizations and need for systemic antibiotics in CF patients.

Conclusions:

  • Inhaled tobramycin demonstrates significant benefits for CF patients, improving outcomes and reducing healthcare utilization.
  • Further research is needed for efficacy in non-CF bronchiectasis and ventilator-associated pneumonia.
  • Tobramycin holds potential for treating various respiratory conditions beyond CF.
Abstract

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...